ENGN (enGene Therapeutics Inc. Common Stock) Stock Analysis - News
enGene Therapeutics Inc. Common Stock (ENGN) is a publicly traded Healthcare sector company. As of May 21, 2026, ENGN trades at $1.55 with a market cap of $105.17M and a P/E ratio of 0.70. ENGN moved +5.88% today. Year to date, ENGN is -81.56%; over the trailing twelve months it is -61.67%. Its 52-week range spans $1.40 to $12.25. Analyst consensus is buy with an average price target of $8.69. Rallies surfaces ENGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ENGN news today?
Analysts Slash enGene Price Targets 40% After ENG-1 Trial Misses Endpoints: Three Wall Street analysts downgraded enGene Therapeutics shares after interim data from its Phase Ib/II ENG-1 trial failed to reach primary efficacy and safety endpoints, prompting average price-target cuts of 40% to a $5–$7 range. Jefferies, SVB Leerink and RBC each shifted ratings from Buy to Hold.
Analysts Slash enGene Price Targets 40% After ENG-1 Trial Misses Endpoints: Three Wall Street analysts downgraded enGene Therapeutics shares after interim data from its Phase Ib/II ENG-1 trial failed to reach primary efficacy and safety endpoints, prompting average price-target cuts of 40% to a $5–$7 range. Jefferies, SVB Leerink and RBC each shifted ratings from Buy to Hold.
Does Rallies summarize ENGN news?
Yes. Rallies summarizes ENGN news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ENGN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ENGN. It does not provide personalized investment advice.
